Form 4: Boston Scientific Executive Sells Shares Under Pre-Arranged Trading Plan

Jeffrey B. Mirviss, EVP & President of Peripheral Interventions at Boston Scientific, sold shares of common stock under a pre-established Rule 10b5-1 trading plan.

Summary

• Jeffrey B. Mirviss, an Executive Vice President at Boston Scientific, sold shares of the company's common stock.
• The sales occurred on February 24, 2025, and February 25, 2025.
• On February 24, 2025, 4,675 shares were sold at a price of $104.25 per share.
• On February 25, 2025, 2,688 shares were sold at a price of $104.25 per share.
• These transactions were executed under a pre-established Rule 10b5-1 trading plan adopted on November 21, 2024.
• Following these transactions, Mirviss directly owns 25,766 shares of Boston Scientific common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document simply reports the sale of shares by an executive under a pre-arranged trading plan. This is a routine transaction and doesn't necessarily indicate a positive or negative outlook for the company.

Positives

• The sales were conducted under a pre-established Rule 10b5-1 trading plan, which is a legal and transparent way for insiders to sell shares.

Future Outlook

NA

Industry Context

Insider sales are a common occurrence in publicly traded companies. The use of a 10b5-1 plan suggests the sales were planned in advance and not based on any material non-public information.

Key Dates